ArticleRadiology2024
Diagnostic Performance of Point-of-Care Apparent Diffusion Coefficient Measures to Reduce Biopsy in Breast Lesions at MRI: Clinical Validation.
Article in Radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07598084 (Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Artificial Intelligence Solution for Simplifying the Diagnostic Workflow of Breast MRI: Development and Clinical Validation of a Diffusion-Weighted Imaging-Based Synthetic Contrast-Enhanced MRI System for Non-Contrast Breast Cancer Diagnosis and Risk Stratification
Who cites it
13 citing papers in PubMed.
- Influence of co-registration on lesion characterization in diffusion-weighted breast MRI.Magma (New York, N.Y.) · 2026Article
- Establishing an Evidence-based Modern Breast MRI Program.Journal of breast imaging · 2026Review
- Diagnostic performance of Kaiser score, ADC, and their combination for BI-RADS 4 breast lesions: subgroup and misclassification analysis.Frontiers in oncology · 2026Article
- Reducing breast biopsy at MRI: comparison of minimum ADC cutoff and mean ADC cutoff identified by the ECOG-ACRIN A6702 multicenter trial.BMC cancer · 2025Article
- Ultrafast MRI and diffusion-weighted imaging: a review of morphological evaluation and image quality in breast MRI.Japanese journal of radiology · 2025Review
- Time to Enhancement Measured From Ultrafast Dynamic Contrast-Enhanced MRI for Improved Breast Lesion Diagnosis.Journal of breast imaging · 2025Article
- Breast Diffusion-weighted MR Imaging: Current Applications, Insights from Screening, and Future Directions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Preoperative Diagnosis of Ipsilateral and Contralateral Breast Cancer: Role of Diffusion-weighted MRI.Radiology · 2025Article
- A large model for non-invasive and personalized management of breast cancer from multiparametric MRI.Nature communications · 2025Article
- Standardization and advancements efforts in breast diffusion-weighted imaging.Japanese journal of radiology · 2025Review
- External validation of multiparametric magnetic resonance imaging-based decision rules for characterizing breast lesions and comparison to Kaiser score and breast imaging reporting and data system (BI-RADS) category.Quantitative imaging in medicine and surgery · 2025Article
- Diffusion weighted imaging for improving the diagnostic performance of screening breast MRI: impact of apparent diffusion coefficient quantitation methods and cutoffs.Frontiers in oncology · 2024Article
- An XGBoost Machine Learning Based Model for Predicting Ki-67 Value ≥ 15% in TTechnology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background The Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group multicenter A6702 trial identified an optimal apparent diffusion coefficient (ADC) cutoff to potentially reduce biopsies by 21% without affecting sensitivity. Whether this performance can be achieved in clinical settings has not yet been established. Purpose To validate the performance of point-of-care ADC measurements with the A6702 trial ADC cutoff for reducing unnecessary biopsies in lesions detected at breast MRI. Materials and Methods Consecutive breast MRI examinations performed from May 2015 to January 2019 at a single medical center and showing biopsy-confirmed Breast Imaging Reporting and Data System category 4 or 5 lesions, without ipsilateral cancer, were identified. Point-of-care lesion ADC measurements collected at clinical interpretation were retrospectively evaluated. MRI examinations included axial T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences. Sensitivity and biopsy reduction rates were calculated by applying the A6702 optimal (ADC, 1.53 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.